ClinicalTrials.gg
RecruitingNCT05785065SSc-mILDUpdated Sep 29, 2026

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

A Phase 2 interventional study of Mycophenolate Mofetil and Placebo in Systemic Sclerosis With Lung Involvement, Systemic Sclerosis and Interstitial Lung Disease, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Other

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Scleroderma, Systemic with a site in Canada — 12 open to participants now, 13 under way, 4 of them phase 3. Scleroderma, Systemic · Canada.

Planned enrollment
30th of 39
35 · median 115
Started
2024
with 1 other
Phase 2
13 of 44
3 open now
Primary completion
2026-12
later than 1 of 12 live
Registered
34th of 44
by date

Among the 44 studies in Scleroderma, Systemic with a site in Canada, this one is the 30th largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 34th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

12 of the 44 studies in Scleroderma, Systemic with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Scleroderma, Systemic with a site in Canada, or all of them as a file.
02

Study summary

The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.

Read the detailed description

Background: Systemic sclerosis (SSc, scleroderma) is a rare but life-threatening systemic autoimmune disease characterized by microvasculopathy, serum autoantibodies, inflammation and fibrosis of the skin and internal organs. Early rapidly progressive SSc remains the most lethal autoimmune rheumatic disease, with over 60% mortality at 5 years in high-risk patients. Interstitial lung disease (ILD) is the leading cause of SSc-related mortality and affects over half of SSc patients. SSc-ILD is currently treated with immunosuppressive and anti-fibrotic drugs, with the first-line treatment being mycophenolate mofetil (MMF), although treatments have modest benefits when initiated in advanced stages of disease. Emerging data suggest that earlier treatment, when lung function is still normal despite evidence of ILD on computed tomography scan ("subclinical SSc-ILD"), may lead to improved outcomes, suggesting a window of treatment opportunity.

Research Aims: The goal of the proposed pilot RCT is to establish the feasibility of a phase III RCT that will assess the efficacy of MMF in subclinical SSc-ILD. Specifically, we aim to:

  1. Determine the rate of patient recruitment at three centers over one year, and identify barriers and solutions to recruitment;
  2. Determine the proportion of participants receiving the allocated treatment and with complete primary efficacy outcome data at 48 and 96 weeks; and
  3. Generate preliminary data on clinical efficacy outcomes that will contribute information to the analysis of the phase III trial through a Bayesian inference framework.

Methods: Participants will be adults with SSc, ILD diagnosed within the past 3 years and a normal forced vital capacity (≥ 80%). Participants will be recruited over 12 months at 3 academic centers affiliated to the Canadian Scleroderma Research Group. Eligible participants will be assigned using stratified randomization to receive either MMF (up to 2 grams daily) or placebo for 96 weeks. The primary feasibility outcome will be the rate of recruitment per site over 12 months. A Bayesian approach will be used to estimate the probability of reaching the target sample size based on observed recruitment rates, with decision rules to continue, adapt, or stop the trial. Data collected on the primary clinical efficacy outcome (annual rate of decline in forced vital capacity over 96 weeks) will be used to inform the analysis of the phase III trial (as an informative prior) through a Bayesian inference framework.

03

Conditions studied

  • Systemic Sclerosis With Lung Involvement
  • Systemic Sclerosis
  • Interstitial Lung Disease

Keywords

  • Systemic sclerosis
  • Mycophenolate mofetil
  • Interstitial lung disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide and adhere to study protocol;
  2. Women and men of all race/ethnicity, aged 18 years and older;
  3. SSc based on 2013 ACR-EULAR classification criteria;
  4. Presence of interstitial lung disease on HRCT scan, obtained within 12 months before screening, that shows fibrosis affecting less than 20% of the lungs, as confirmed by an expert radiologist;
  5. Diagnosis of ILD within 7 years before screening;
  6. Forced vital capacity of 80% predicted and above, on pulmonary function tests obtained within 6 months before screening;
  7. Able to communicate in French or English;

Exclusion criteria

Exclusion Criteria:

  1. Progressive pulmonary fibrosis, defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation, as defined by the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline;
  2. Use of medications with putative lung disease-modifying properties:

    1. Current use of MMF, mycophenolic acid, azathioprine, calcineurin inhibitors (e.g. tacrolimus, cyclosporin A), tocilizumab, nintedanib, pirfenidone or (Prednisone equivalent dose >10 mg/day) at time of screening
    2. Cyclophosphamide within one year prior to screening
    3. Rituximab within 6 months prior to screening
    4. Cell therapies (including stem cell transplantation) within one year prior to screening
  3. Current use of other biological, targeted synthetic or products with effects (e.g. TNF inhibitors, abatacept, tofacitinib) at time of screening
  4. Any to MMF, including:

    1. Pregnancy and/or breastfeeding
    2. Female of not using reliable method of
    3. Persistent leucopenia (white blood cell count \<3.0 x103/μL)
    4. Persistent thrombocytopenia ( count \<100 x103/μL)
    5. Persistent anemia ( \<100 g/L)
    6. Baseline liver enzymes ( (ALT) or aspartate transaminase (AST)) or >1.5 times the , other than due to Gilbert's disease
    7. Uncontrolled congestive heart failure
    8. Active infection (lung or elsewhere)
    9. Active solid or hematological (other than basal cell cancer of the skin or cervical carcinoma in situ removed entirely by )
    10. Active peptic ulcer disease
    11. Other serious concomitant medical illness, unreliability or drug abuse that might compromise the patient's ability to safely take MMF
    12. Use of drugs or products with significant interactions with MMF
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Mycophenolate mofetil

    2 to 4 capsules of mycophenolate mofetil twice daily.

    Drug: Mycophenolate Mofetil

  • Placebo comparator
    Placebo

    2 to 4 capsules of placebo twice daily.

    Other: Placebo

Interventions

  • The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks. The dose scheduling will be as follow: Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day

  • OtherPlacebo

    The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks. The dose scheduling will be as follow: Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day

06

What researchers measure

Primary outcomes

  1. Total number of potentially eligible patients identified per site

    Time frame: Over one year

  2. Proportion of potentially eligible patients who provide consent per site

    Time frame: Over one year

  3. Proportion of consented participants who meet the eligibility criteria per site

    Time frame: Over one year

  4. Monthly rate of randomized participants per site

    Time frame: Over one year

  5. Adherence to treatment as assessed by Participant Dosing Diaries

    Time frame: From the first dose to the last dose taken for each participant, up to 96 weeks

  6. Drug adherence rate as assessed by Pharmacy Accountability Logs

    Time frame: From the first dose to the last dose taken for each participant, up to 96 weeks

  7. Adherence to the study protocol as assessed by the number of protocol deviations

    Time frame: Over total study period (up to 96 weeks per participant)

  8. Proportion of participants intolerant to the study drug who discontinue trial treatment

    Time frame: Over total study period (up to 96 weeks per participant)

  9. Proportion of participants receiving the allocated treatment at 48 weeks

    Time frame: At 48 weeks

  10. Proportion of participants receiving the allocated treatment at 96 weeks

    Time frame: At 96 weeks

  11. Proportion of participants with complete primary efficacy outcome data at 48 weeks

    Time frame: At 48 weeks

  12. Proportion of participants with complete primary efficacy outcome data at 96 weeks

    Time frame: At 96 weeks

  13. Proportion of participants lost to follow-up

    Time frame: Over total study period (up to 96 weeks per participant)

Secondary outcomes

  1. Frequency of treatment-related adverse events

    Incidence and severity of AEs, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    Time frame: Over total study period (up to 96 weeks per participant)

Other outcomes

  1. Annual rate of decline in percent (%) predicted forced vital capacity (FVC) over 48 weeks

    Time frame: Over 48 weeks

  2. Annual rate of decline in percent (%) predicted forced vital capacity (FVC) over 96 weeks

    Time frame: Over 96 weeks

  3. Proportion of participants having clinically meaningful progression

    Clinically meaningful progression defined by the Outcome Measures in Rheumatology (OMERACT) for connective tissue disease-associated interstitial lung diseases (CTD-ILD) (defined as a ≥10% relative decline in FVC from baseline, or a ≥5% to \<10% relative decline in FVC associated with a ≥15% relative decline in diffusion capacity \[DLCO\])

    Time frame: Over total study period (up to 96 weeks per participant)

  4. Time to clinically meaningful progression

    Clinically meaningful progression as defined by Outcome Measures in Rheumatology (OMERACT) for connective tissue disease- associated interstitial lung diseases (CTD-ILD) (defined as a ≥10% relative decline in FVC from baseline, or a ≥5% to \<10% relative decline in FVC associated with a ≥15% relative decline in diffusion capacity \[DLCO\])

    Time frame: Over total study period (up to 96 weeks per participant)

  5. Proportion of participants having an absolute decrease in FVC of at least 3.3% predicted

    An absolute decrease in FVC of at least 3.3% predicted was proposed as the minimal clinically important difference estimate for worsening of FVC in patients with SSc-ILD.

    Time frame: Over total study period (up to 96 weeks per participant)

  6. Time to an absolute decrease in FVC of at least 3.3% predicted

    An absolute decrease in FVC of at least 3.3% predicted was proposed as the minimal clinically important difference estimate for worsening of FVC in patients with SSc-ILD.

    Time frame: Over total study period (up to 96 weeks per participant)

  7. Proportion of participants having progressive pulmonary fibrosis

    Progressive pulmonary fibrosis defined by 2022 ATS/ERS/JRS/ALAT guidelines

    Time frame: Over total study period (up to 96 weeks per participant)

  8. Time to progressive pulmonary fibrosis

    Progressive pulmonary fibrosis defined by 2022 ATS/ERS/JRS/ALAT guidelines

    Time frame: Over total study period (up to 96 weeks per participant)

  9. Annual rate of decline in percent (%) predicted total lung capacity over 48 weeks

    Time frame: Over 48 weeks

  10. Annual rate of decline in percent (%) predicted total lung capacity over 96 weeks

    Time frame: Over 96 weeks

  11. Annual rate of decline in percent (%) predicted diffusion capacity for carbon monoxide (DLCO) over 48 weeks

    Time frame: Over 48 weeks

  12. Annual rate of decline in percent (%) predicted DLCO over 96 weeks

    Time frame: Over 96 weeks

  13. Change from baseline in percent (%) extent of ILD, ground-glass opacities, reticular infiltrates and honeycombing, and in pulmonary vessel volume at 48 weeks

    Measured on high-resolution computed tomography chest scan using automated lung texture analysis

    Time frame: At 48 weeks

  14. Change from baseline in percent (%) extent of ILD, ground-glass opacities, reticular infiltrates and honeycombing, and in pulmonary vessel volume at 96 weeks

    Measured on high-resolution computed tomography chest scan using automated lung texture analysis

    Time frame: At 96 weeks

  15. Change from baseline in St-George Respiratory Questionnaire at 48 weeks

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At 48 weeks

  16. Change from baseline in St-George Respiratory Questionnaire at 96 weeks

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At 96 weeks

  17. Change from baseline in Leicester Cough Questionnaire at 48 weeks

    Scores (total) range from 3 to 21, with higher scores indicating less limitations.

    Time frame: At 48 weeks

  18. Change from baseline in Leicester Cough Questionnaire at 96 weeks

    Scores (total) range from 3 to 21, with higher scores indicating less limitations.

    Time frame: At 96 weeks

  19. Change from baseline in health assessment questionnaire modified for scleroderma at 48 weeks

    The SHAQ consists of the Health assessment questionnaire (HAQ) and visual analogue scales for pain, patient global assessment, vascular, digital ulcers, lung involvement and gastrointestinal involvement. Scores range from 0 to 3, with higher scores indicating more limitations.

    Time frame: At 48 weeks

  20. Change from baseline in health assessment questionnaire modified for scleroderma at 96 weeks

    The SHAQ consists of the Health assessment questionnaire (HAQ) and visual analogue scales for pain, patient global assessment, vascular, digital ulcers, lung involvement and gastrointestinal involvement. Scores range from 0 to 3, with higher scores indicating more limitations.

    Time frame: At 96 weeks

  21. Change from baseline in 36-items short form survey (SF-36) at 48 weeks

    Eight scales with scores range from 0 to 100, with higher scores indicating less limitations.

    Time frame: At 48 weeks

  22. Change from baseline in 36-items short form survey (SF-36) at 96 weeks

    Eight scales with scores ranging from 0 to 100, with higher scores indicating less limitations.

    Time frame: At 96 weeks

  23. Change from baseline in EuroQoL five dimensions (EQ-5D-5L) at 48 weeks

    The EQ-5D-5L questionnaire possesses 5 levels for each of the five dimensions. The five dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with the following possible five responses: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Scores are converted into an index value ranging from 0 to 1, with higher scores indicating better health state.

    Time frame: At 48 weeks

  24. Change from baseline in EuroQoL five dimensions (EQ-5D-5L) at 96 weeks

    The EQ-5D-5L questionnaire possesses 5 levels for each of the five dimensions. The five dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with the following possible five responses: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Scores are converted into an index value ranging from 0 to 1, with higher scores indicating better health state.

    Time frame: At 96 weeks

  25. Change from baseline in patient global assessment at 48 weeks

    Visual analogue scale from 0 to 10, with higher scores indicating worse disease.

    Time frame: At 48 weeks

  26. Change from baseline in patient global assessment at 96 weeks

    Visual analogue scale from 0 to 10, with higher scores indicating worse disease.

    Time frame: At 96 weeks

  27. Change from baseline in physician global assessment at 48 weeks

    Visual analogue scale from 0 to 10, with higher scores indicating worse disease.

    Time frame: At 48 weeks

  28. Change from baseline in physician global assessment at 96 weeks

    Visual analogue scale from 0 to 10, with higher scores indicating worse disease.

    Time frame: At 96 weeks

  29. Change from baseline in 6-minute walk oxygen saturation at 48 weeks

    Oxygen saturation at nadir during the 6-minute walk test

    Time frame: At 48 weeks

  30. Change from baseline in 6-minute walk oxygen desaturation at 96 weeks

    Oxygen saturation at nadir during the 6-minute walk test

    Time frame: At 96 weeks

  31. Change from baseline in modified Rodnan skin score (mRSS) at 48 weeks

    Scores range from 0 to 51, with higher scores indicating more skin involvement.

    Time frame: At 48 weeks

  32. Change from baseline in modified Rodnan skin score (mRSS) at 96 weeks

    Scores range from 0 to 51, with higher scores indicating more skin involvement.

    Time frame: At 96 weeks

  33. Change from baseline in nailfold capillary density at 48 weeks

    Mean number of capillaries per mm

    Time frame: At 48 weeks

  34. Change from baseline in nailfold capillary density at 96 weeks

    Mean number of capillaries per mm

    Time frame: At 96 weeks

  35. Change from baseline in nailfold capillaroscopy abnormalities and patterns at 48 weeks

    Ectasias/megacapillaries are scored using a semi-quantitative scale (0 = no, 1 = ≤33%, 2= 33-66%, and 3 = ≥66% abnormalities/linear mm)

    Time frame: At 48 weeks

  36. Change from baseline in nailfold capillaroscopy abnormalities and patterns at 96 weeks

    Ectasias/megacapillaries are scored using a semi-quantitative scale (0 = no, 1 = ≤33%, 2= 33-66%, and 3 = ≥66% abnormalities/linear mm)

    Time frame: At 96 weeks

  37. Change from baseline in quantitative SSc autoantibody titers at 48 weeks

    Time frame: At 48 weeks

  38. Change from baseline in quantitative SSc autoantibody titers at 96 weeks

    Time frame: At 96 weeks

  39. Change from baseline in Krebs von Lungen 6 (KL-6) titers at 48 weeks

    Time frame: At 48 weeks

  40. Change from baseline in Krebs von Lungen 6 (KL-6) titers at 96 weeks

    Time frame: At 96 weeks

07

Study locations

1 of 3 sites recruiting
  • Centre hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
  • Jewish General Hospital - CIUSSS-COMTL
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
    • Marie Hudson, MD · Contact
    • Marie Hudson, MD · Principal investigator
  • Institut Universitaire de Cardiologie et Pneumologie de Québec
    Québec, Quebec, Canada
    Not yet recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 28 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Dec 2023 → Aug 2024, primary completion Dec 2024 → Dec 2026 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Mar 27, 2023
StartActual
Aug 29, 2024was Dec 2023
Primary completionEst.
Dec 2026was Dec 2024
CompletionEst.
Dec 2028was Dec 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
1 site added, 1 site removed. 2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Canadano status→Recruiting
  • Jewish General Hospital - CIUSSS-COMTL · Montreal, Canadano status→Not yet recruiting
Show site
  • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, Canada
Show 1 removed
  • St-Joseph's Healthcare Hamilton · Hamilton, Canada
Sep 29, 2026
Start date
Dec 2023→Aug 29, 2024 (actual)
Sep 29, 2026
Primary completion
Dec 2024→Dec 2026
Sep 29, 2026
Study completion
Dec 2026→Dec 2028
Sep 29, 2026
Contact
Study contact changed: j•••@ssss.gouv.qc.ca · •••8000→s•••@ssss.gouv.qc.ca · •••8000; s•••@ssss.gouv.qc.ca · •••8000→u•••@ssss.gouv.qc.ca. See the current contact
Sep 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, CanadaContact j•••@ssss.gouv.qc.ca · •••8000→u•••@ssss.gouv.qc.ca · •••8000Contact person changed (no phone or email listed)
Sep 29, 2026
Sponsor
Collaborators added: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval; collaborators removed: St. Joseph's Healthcare Hamilton
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed. 2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Canadano status→Recruiting
    • Jewish General Hospital - CIUSSS-COMTL · Montreal, Canadano status→Not yet recruiting
    Show site
    • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, Canada
    Show 1 removed
    • St-Joseph's Healthcare Hamilton · Hamilton, Canada
    Start date Dec 2023→Aug 29, 2024 (now actual)
    Primary completion Dec 2024→Dec 2026
    Study completion Dec 2026→Dec 2028
    Sponsor Collaborators added: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval; collaborators removed: St. Joseph's Healthcare Hamilton
    Contact Study contact changed: j•••@ssss.gouv.qc.ca · •••8000→s•••@ssss.gouv.qc.ca · •••8000; s•••@ssss.gouv.qc.ca · •••8000→u•••@ssss.gouv.qc.ca. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, CanadaContact j•••@ssss.gouv.qc.ca · •••8000→u•••@ssss.gouv.qc.ca · •••8000Contact person changed (no phone or email listed)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05785065
Collaborators
McGill University, University of Calgary, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Sclérodermie Québec, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Aug 29, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Sabrina Hoa, MD MSc
Contact
sabrina.anh-tu.hoa.med@ssss.gouv.qc.ca
514-890-8000
Unité d'innovation thérapeutique, CHUM
Contact
uit.eligibilite.chum@ssss.gouv.qc.ca
Sabrina Hoa, MD
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mycophenolic Acid

Start the discussion